Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics Corp. announced promising clinical trial results for its immunotherapy drug MDNA11, showing significant tumor regression in melanoma and pancreatic cancer patients who were previously resistant to other treatments. The company has also secured a financial investment extending its operational runway to mid-2026 and plans to present further updates in the second half of 2024.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
